CompletedNCT00271258
Six months of divalproex treatment for mania in adolescents with bipolarity
About this title
Safety Study of Sodium Divalproate in Bipolar Disorder in Adolescents
Read the official source — NCT00271258Medication studyAges 13–18France
Understand this study
Who was this study for?
Listed age limits: 13 years to 18 years.
- Listed locations
- ParisSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJanuary 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 200
- Sponsor
- Sanofi
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- France
- Age range
- From 13 Years to 18 Years
- Official registry ID
- NCT00271258
- Official title
Show the full official title
STUDY OF THE TOLERANCE OF SODIUM DIVALPROATE (DEPAKOTE) IN ADOLESCENTS IN MANIC, MIXED OR HYPOMANIC EPISODES OF BIPOLAR DISORDER
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedParis
Questions about this study
Who is behind this study?
The study sponsor is Sanofi.
Did this study involve medication?
Yes. The study involved medication, including SODIUM DIVALPROATE.
Who was this study for?
Listed age limits: 13 years to 18 years.
Want to explore more studies?
Explore studiesRelated studies
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolarity type I Pat...
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression